These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1102242)

  • 1. Panel 3: phase III investigations.
    Azarnoff DL; Abrams WB; Cuttner J; Hewitt WL; Hailman HF
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):650-2. PubMed ID: 1102242
    [No Abstract]   [Full Text] [Related]  

  • 2. The assessment of adverse drug reactions in clinical trials.
    Petrie WM; Levine J
    Int Pharmacopsychiatry; 1978; 13(4):209-16. PubMed ID: 730486
    [No Abstract]   [Full Text] [Related]  

  • 3. Panel 4: phase IV investigations.
    Blackwell B; Stolley PD; Buncher R; Klimt CR; Temple R; Venn D; Wardell WM
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):653-6. PubMed ID: 1102243
    [No Abstract]   [Full Text] [Related]  

  • 4. Patients' needs in drug development and regulation.
    Wardell WM
    Ann N Y Acad Sci; 1981; 368():187-202. PubMed ID: 7020538
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of the Drug Regulation Reform Act of 1978 on clinical research, drug availability, and the public health.
    Temple RJ
    Ann N Y Acad Sci; 1981; 368():175-85. PubMed ID: 7020537
    [No Abstract]   [Full Text] [Related]  

  • 6. Some observations on the collection of medical event data.
    Mohberg NR
    Drug Inf J; 1987; 21(1):55-62. PubMed ID: 10301497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives.
    Cutler NR; Sramek JJ; Greenblatt DJ; Chaikin P; Ford N; Lesko LJ; Davis B; Williams RL
    J Clin Pharmacol; 1997 Sep; 37(9):767-83. PubMed ID: 9549630
    [No Abstract]   [Full Text] [Related]  

  • 8. Consider drug efficacy before first-in-human trials.
    Kimmelman J; Federico C
    Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789
    [No Abstract]   [Full Text] [Related]  

  • 9. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug hepatotoxicity from a regulatory perspective.
    Senior JR
    Clin Liver Dis; 2007 Aug; 11(3):507-24, vi. PubMed ID: 17723917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety Reporting: It Can Enter the 21st Century-If We Let It.
    Seltzer J; Bhattacharyya A
    Ther Innov Regul Sci; 2018 May; 52(3):354-361. PubMed ID: 29714542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of drugs from the viewpoint of the Food and Drug Administration.
    Crout JR
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):634-6. PubMed ID: 1102238
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovering adverse drug reactions.
    Lasagna L
    JAMA; 1983 Apr 22-29; 249(16):2224-5. PubMed ID: 6339764
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase 3 trials and drug labeling.
    Am J Cardiol; 1974 Oct; 34(4):481-2. PubMed ID: 4415044
    [No Abstract]   [Full Text] [Related]  

  • 16. Panel 2: phase II investigations.
    Hollister LE; Martz BL; Carr EA; Cohn HD; Crout JR; Levine J
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):647-9. PubMed ID: 1102241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 18. Sounding board. Creative tension: FDA and medicine.
    Kennedy D
    N Engl J Med; 1978 Apr; 298(15):846-50. PubMed ID: 345121
    [No Abstract]   [Full Text] [Related]  

  • 19. The United States Food and Drug Administration guidelines on ambulatory blood pressure monitoring.
    Lipicky R
    J Hypertens Suppl; 1991 Dec; 9(8):S59. PubMed ID: 1795204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panel 1: phase I investigations.
    Goldberg LI; Besselaar GH; Arnold JD; Lemberger L; Mitchell JR; Whitsett TL
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):643-6. PubMed ID: 1102240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.